<table>
<thead>
<tr>
<th>Code</th>
<th>Short Descriptor</th>
<th>Long Descriptor</th>
<th>Payment</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>M0220</td>
<td>TIXAGEV AND CILGAV INJ</td>
<td>INJECTION, TIXAGEVIMAB AND CILGAVIMAB, FOR THE PRE-EXPOSURE PROPHYLAXIS ONLY, FOR CERTAIN ADULTS AND PEDIATRIC INDIVIDUALS (12 YEARS OF AGE AND OLDER WEIGHING AT LEAST 40KG) WITH NO KNOWN</td>
<td>$150.50</td>
<td>eff 12/8/21</td>
</tr>
<tr>
<td>M0221</td>
<td>TIXAGEV AND CILGAV INJ HM</td>
<td>INJECTION, TIXAGEVIMAB AND CILGAVIMAB, FOR THE PRE-EXPOSURE PROPHYLAXIS ONLY, FOR CERTAIN ADULTS AND PEDIATRIC INDIVIDUALS (12 YEARS OF AGE AND OLDER WEIGHING AT LEAST 40KG) WITH NO KNOWN</td>
<td>$250.50</td>
<td>eff 12/8/21</td>
</tr>
<tr>
<td>M0222</td>
<td>BEBTELOVIMAB INJECTION</td>
<td>INTRAVENOUS INJECTION, BEBTELOVIMAB, INCLUDES INJECTION AND POST ADMINISTRATION MONITORING</td>
<td>$350.50</td>
<td>eff 2/11/22</td>
</tr>
<tr>
<td>M0223</td>
<td>BEBTELOVIMAB INJECTION HOME</td>
<td>INTRAVENOUS INJECTION, BEBTELOVIMAB, INCLUDES INJECTION AND POST ADMINISTRATION MONITORING IN THE HOME OR RESIDENCE; THIS INCLUDES A BENEFICIARY'S HOME THAT HAS BEEN MADE PROVIDER-BASED TO THE HOSPITAL DURING THE COVID-19 PUBLIC HEALTH EMERGENCY</td>
<td>$550.50</td>
<td>eff 2/11/22</td>
</tr>
<tr>
<td>M0240</td>
<td>Casirivi and imdevi repeat</td>
<td>Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses</td>
<td>$450.00</td>
<td>eff 10/1/21</td>
</tr>
<tr>
<td>M0241</td>
<td>Casirivi and imdevi repeat hm</td>
<td>Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence, this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses</td>
<td>$750.00</td>
<td>eff 10/1/21</td>
</tr>
<tr>
<td>M0243</td>
<td>Casirivi and imdevi inj</td>
<td>Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring</td>
<td>$450.00</td>
<td>eff 11/21/20, new Rate effective 10/1/21</td>
</tr>
<tr>
<td>M0244</td>
<td>Casirivi and imdevi inj hm</td>
<td>Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency</td>
<td>$750.00</td>
<td>eff 5/6/2, new rate effective 10/1/21</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>Details</td>
<td>Price</td>
<td>Effective Dates</td>
</tr>
<tr>
<td>--------</td>
<td>------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>---------</td>
<td>-----------------</td>
</tr>
<tr>
<td>M0245</td>
<td>Bamlan and etesev infusion</td>
<td>Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring</td>
<td>$450.00</td>
<td>2/9/21</td>
</tr>
<tr>
<td>M0246</td>
<td>Bamlan and etesev infusion home</td>
<td>Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the covid-19 public health emergency</td>
<td>$750.00</td>
<td>5/6/21, new rate effective 10/1/21</td>
</tr>
<tr>
<td>M0247</td>
<td>Sotrovimab infusion</td>
<td>Intravenous infusion, sotrovimab, includes infusion and post administration monitoring</td>
<td>$450.00</td>
<td>10/1/21</td>
</tr>
<tr>
<td>M0248</td>
<td>Sotrovimab inf, home admin</td>
<td>Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the covid-19 public health emergency</td>
<td>$750.00</td>
<td>10/1/21</td>
</tr>
<tr>
<td>M0249</td>
<td>Adm Tocilizu COVID-19 1st</td>
<td>Intravenous infusion, tocilzumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, first dose</td>
<td>$450.00</td>
<td>10/1/21</td>
</tr>
<tr>
<td>M0250</td>
<td>Adm Tocilizu COVID-19 2nd</td>
<td>Intravenous infusion, tocilzumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, second dose</td>
<td>$450.00</td>
<td>10/1/21</td>
</tr>
<tr>
<td>Q0220</td>
<td>TIXAGEV AND CILGAV, 300MG</td>
<td>INJECTION, TIXAGEVIMAB AND CILGAVIMAB, FOR THE PRE-EXPOSURE PROPHYLAXIS ONLY, FOR CERTAIN ADULTS AND PEDIATRIC INDIVIDUALS (12 YEARS OF AGE AND OLDER WEIGHING AT LEAST 40KG) WITH NO KNOWN</td>
<td>$0.00</td>
<td>12/8/21</td>
</tr>
<tr>
<td>Q0221</td>
<td>TIXAGEV AND CILGAV, 600MG</td>
<td>INJECTION, TIXAGEVIMAB AND CILGAVIMAB, FOR THE PRE-EXPOSURE PROPHYLAXIS ONLY, FOR CERTAIN ADULTS AND PEDIATRIC INDIVIDUALS (12 YEARS OF AGE AND OLDER WEIGHING AT LEAST 40KG) WITH NO KNOWN</td>
<td>$0.00</td>
<td>2/24/22</td>
</tr>
<tr>
<td>Q0222</td>
<td>BEBTELOVIMAB 175 MG</td>
<td>INJECTION, BEBTELOVIMAB, 175 MG</td>
<td>$2,394.00</td>
<td>2/11/22</td>
</tr>
</tbody>
</table>